Mirvetuximab soravtansine (MIRV) is an ADC that was approved by the FDA in 2022 for the treatment of folate receptor alpha-positive, platinum-resistant ovarian, fallopian tube or peritoneal cancer[10]. This evidence concerns the gene FOLR1 and peritoneum cancer.